SG11201407110QA - Novel dosage form and formulation of abediterol - Google Patents

Novel dosage form and formulation of abediterol

Info

Publication number
SG11201407110QA
SG11201407110QA SG11201407110QA SG11201407110QA SG11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA
Authority
SG
Singapore
Prior art keywords
international
barcelona
abediterol
llobregat
laurea
Prior art date
Application number
SG11201407110QA
Inventor
Ruiz Sandrine Allain
Nunez Beatriz Seoane
Miquel Serra Gonzalo De
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407110Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of SG11201407110QA publication Critical patent/SG11201407110QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/178742 A1 (51) International Patent Classification: A61K 9/14 (2006.01) A61P11/08 (2006.01) A61K31/4706 (2006.01) A61P11/06 (2006.01) A61K9/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/061181 30 May 2013 (30.05.2013) English (30) Priority Data: 12382221.5 61/660,003 31 May 2012 (31.05.2012) 15 June 2012 (15.06.2012) English EP US (71) Applicant: ALMIRALL, S.A. [ES/ES]; Ronda del Gener­ al Mitre 151, E-08022 Barcelona (ES). (72) Inventors: ALLAIN RUIZ, Sandrine; C/O Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). SEOANE NUNEZ, Beatriz; C/O Laurea Miro 408- 410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). DE MIQUEL SERRA, Gonzalo; C/O Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). (74) Agent: SRINIVASAN, Ravi Chandran; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) CJ •t l> 00 l> i-H ^ (54) Title: NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL 5 (57) Abstract: The present invention provides pharmaceutical a composition in the form of a dry powder for inhalation comprising C^l abediterol or a pharmaceutically acceptable salt in admixture with pharmaceutically acceptable carrier, a providing upon inhalation a dose equivalent to a metered nominal dose of about 1.25 or about 2.5 micrograms of free base abediterol administered with the Gen - (5T uair® inhaler. The present invention also provides said pharmaceutical composition for use in the treatment of respiratory disease 5- such as asthma and chronic obstructive pulmonary disease COPD.
SG11201407110QA 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol SG11201407110QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
US201261660003P 2012-06-15 2012-06-15
PCT/EP2013/061181 WO2013178742A1 (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Publications (1)

Publication Number Publication Date
SG11201407110QA true SG11201407110QA (en) 2014-12-30

Family

ID=46317311

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201407110QA SG11201407110QA (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol
SG10201913424SA SG10201913424SA (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol
SG10201609119VA SG10201609119VA (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913424SA SG10201913424SA (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol
SG10201609119VA SG10201609119VA (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Country Status (29)

Country Link
US (2) US20150140099A1 (en)
EP (2) EP2668941A1 (en)
JP (1) JP6272836B2 (en)
KR (2) KR20150018526A (en)
CN (1) CN104394852A (en)
AR (1) AR091233A1 (en)
AU (1) AU2013269565B2 (en)
BR (1) BR112014029735A2 (en)
CA (1) CA2871358C (en)
CL (1) CL2014003286A1 (en)
CO (1) CO7141434A2 (en)
CR (1) CR20140540A (en)
DO (1) DOP2014000271A (en)
EA (1) EA201401354A1 (en)
EC (1) ECSP14028814A (en)
HK (1) HK1203149A1 (en)
IL (1) IL235831B (en)
IN (1) IN2014DN08672A (en)
MX (1) MX2014014350A (en)
MY (1) MY184654A (en)
NI (1) NI201400139A (en)
NZ (1) NZ701261A (en)
PE (1) PE20150171A1 (en)
PH (1) PH12014502662A1 (en)
SG (3) SG11201407110QA (en)
TW (1) TWI610690B (en)
UY (1) UY34838A (en)
WO (1) WO2013178742A1 (en)
ZA (1) ZA201407405B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2015193631A1 (en) * 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
EP4252816A3 (en) 2018-05-22 2024-01-17 C. R. Bard, Inc. Catheterization system and methods for use thereof
JP7314252B2 (en) 2018-08-10 2023-07-25 シー・アール・バード・インコーポレーテッド Automatic urine volume measurement system
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (en) 1979-02-05 1979-02-05 Chiesi Paolo Parma INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (en) 1984-10-04 1986-09-12 Orion Yhtymae Oy DOSERINGSANORDNING
DE3927170A1 (en) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg INHALATOR
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (en) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg GAS-FREE INHALATION DEVICE
DE69132850T2 (en) 1990-09-26 2002-05-29 Pharmachemie Bv Cyclone powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (en) 1992-11-24 1994-05-26 Bayer Ag Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion
CZ287848B6 (en) 1992-12-18 2001-02-14 Schering Corp Inhalator of powder substances
ATE209518T1 (en) 1995-06-21 2001-12-15 Asta Medica Ag MEDICINAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND POWDER INHALER
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
ITMI20010357U1 (en) 2001-06-28 2002-12-30 Plastiape Spa INHALER DEVICE
ES2195785B1 (en) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2211344B1 (en) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
EP1667687A1 (en) * 2003-09-26 2006-06-14 Schering Corporation Pulmonary disease treatment
ES2232306B1 (en) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (en) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2251867B1 (en) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
KR101214823B1 (en) 2004-07-16 2012-12-24 알미랄, 에스.에이. Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
ES2306595B1 (en) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (en) 2008-12-22 2010-05-31 Almirall Sa MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases

Also Published As

Publication number Publication date
BR112014029735A2 (en) 2017-06-27
NZ701261A (en) 2016-08-26
JP6272836B2 (en) 2018-01-31
EA201401354A1 (en) 2015-05-29
CO7141434A2 (en) 2014-12-12
ZA201407405B (en) 2015-11-25
JP2015519356A (en) 2015-07-09
KR20180104197A (en) 2018-09-19
AU2013269565B2 (en) 2017-07-20
CR20140540A (en) 2015-01-16
CL2014003286A1 (en) 2015-02-20
SG10201913424SA (en) 2020-03-30
IL235831A0 (en) 2015-01-29
CA2871358A1 (en) 2013-12-05
CN104394852A (en) 2015-03-04
CA2871358C (en) 2020-09-29
EP2854771A1 (en) 2015-04-08
DOP2014000271A (en) 2015-02-27
US20150140099A1 (en) 2015-05-21
MY184654A (en) 2021-04-14
US20160303108A1 (en) 2016-10-20
SG10201609119VA (en) 2016-12-29
KR20150018526A (en) 2015-02-23
IL235831B (en) 2020-09-30
HK1203149A1 (en) 2015-10-23
WO2013178742A1 (en) 2013-12-05
TW201347789A (en) 2013-12-01
ECSP14028814A (en) 2015-12-31
NI201400139A (en) 2015-12-10
AR091233A1 (en) 2015-01-21
PE20150171A1 (en) 2015-01-31
MX2014014350A (en) 2015-03-03
UY34838A (en) 2014-03-31
EP2668941A1 (en) 2013-12-04
PH12014502662A1 (en) 2015-02-02
TWI610690B (en) 2018-01-11
AU2013269565A1 (en) 2014-10-30
IN2014DN08672A (en) 2015-05-22

Similar Documents

Publication Publication Date Title
SG11201407110QA (en) Novel dosage form and formulation of abediterol
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201407114YA (en) Novel dosage and formulation
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201408261UA (en) Syringe
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201407340YA (en) Treatment of myelosuppression
SG11201408174UA (en) Antibody formulation
SG11201408292YA (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201407837WA (en) Beta-hairpin peptidomimetics
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201809799WA (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders